Filing Flows › Health Care › Kiniksa Pharmaceuticals International (KNSA)
Kiniksa Pharmaceuticals International (KNSA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 27, 2026 · Kiniksa Pharmaceuticals International (KNSA) Q3 2026 earnings results →
Q3 2026 Revenue up 58% year over year to $286M · 17¢ of every $1 of revenue kept as net profit · operating margin 19.0%
Kiniksa Pharmaceuticals International made $286M in Q3 2026 (+58% Y/Y). Operating margin 19.0%, net earnings $47.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $286.0M in Q3 2026, up 58% year over year and up 17% from the previous quarter.
Operating profit was $54.2M, a 19.0% margin (up 5.7 points year over year). Of the extra revenue versus Q3 2025, 29% reached operating profit, above the 13% margin then. Total costs grew 48% against revenue growth of 58%. The fastest-growing cost line was Other operating costs (+67%). Net earnings were $47.3M, up 157% year over year. The effective tax rate was 19.8%.
Operating cash flow was $47.5M (up 41% year over year), 100% of net earnings. Non-cash charges added back $490K of depreciation and amortization and $13.1M of share-based compensation. Working capital and other items used $13.4M. Capital expenditures of $180K left free cash flow of $47.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 27, 2026 | $286M | +58% | 19.0% | $47.3M | $47.5M |
| Q2 2026 | 10-Q | Jul 28, 2026 | $244M | +55% | 11.2% | $25.4M | $47.2M |
| Q1 2026 | 10-Q | Apr 28, 2026 | $214M | +56% | 13.7% | $22.6M | $50.2M |
| Q4 2025 | 10-K | Feb 24, 2026 | $202M | +65% | 9.8% | $14.2M | $53.9M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $181M | +61% | 13.3% | $18.4M | $33.7M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $157M | +44% | 12.9% | $17.8M | $28.1M |
| Q1 2025 | 10-Q | Apr 29, 2025 | $138M | +72% | 9.6% | $8.5M | $22.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Kiniksa Pharmaceuticals International
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.
In its own words, from its 10-K, filed Feb 24, 2026.
Kiniksa Pharmaceuticals International against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +58% against the peers' median +10%. Operating margin: 19.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International | Q3 2026 | $286M | +58% | 19.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR · CIK 1730430 · Pharmaceutical Preparations
Guidance and outlook
More on KNSA
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Kiniksa Pharmaceuticals International guidance history: guided vs reported
- Kiniksa Pharmaceuticals International operating margin by quarter
- Kiniksa Pharmaceuticals International net income by quarter
- Kiniksa Pharmaceuticals International free cash flow by quarter
- Kiniksa Pharmaceuticals International R&D spending by quarter
- Kiniksa Pharmaceuticals International capital expenditures by quarter